Pharmacyclics Inc (PCYC)

PCYC (NASDAQ:Drugs)
$140.33
pos +0.00
+0.00%
Today's Range: 139.14 - 142.90 | PCYC Avg Daily Volume: 797,600
Last Update: 11/21/14 - 3:59 PM EST
Volume: 0
YTD Performance: 32.66%
Open: $0.00
Previous Close: $138.52
52 Week Range: $82.51 - $154.89
Oustanding Shares: 75,539,147
Market Cap: 10,463,682,642
6-Month Chart
TheStreet Ratings Grade for PCYC
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 10 10 11
Moderate Buy 0 0 0 0
Hold 5 5 5 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.67 1.67 1.67 1.53
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 123.68
Price Earnings Comparisons:
PCYC Sector Avg. S&P 500
123.68 125.50 25.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
18.38% 11.29% 1,033.52%
GROWTH 12 Mo 3 Yr CAGR
Revenue 61.90 26.95 2.00
Net Income -43.00 -5.46 0.00
EPS -45.00 -3.97 0.00
Earnings for PCYC:
EBITDA 0.10B
Revenue 0.26B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $0.72 $-0.33 $1.01 $0.07
Number of Analysts 10 2 11 11
High Estimate $0.99 $-0.22 $1.80 $2.56
Low Estimate $0.33 $-0.43 $0.33 $-3.55
Prior Year $0.82 $0.23 $0.87 $1.01
Growth Rate (Year over Year) -11.71% -241.30% 16.41% -93.27%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Bullish
Nov 05, 2014 | 7:01 AM EST
Shares of PCYC now seen reaching $175, according to Nomura. Estimates also upped, given higher expected Imbruvica results. Buy rating.&...
Something worrisome has me fretting more than I have in a while.
Bullish
Jul 29, 2014 | 7:52 AM EDT
PCYC was upgraded from Market Perform to Outperform, Leerink Swann said. $142 price target. Expect that Zydelig and Imbruvica can drive...
Bearish
May 27, 2014 | 7:09 AM EDT
PCYC was downgraded from Outperform to Sector Perform, RBC Capital said. $95 price target. Company is facing potential growth headwinds...
For these names, targets have climbed ahead of earnings releases.
These growth stocks are no longer an anchor to this market.
Bearish
Nov 14, 2013 | 8:05 AM EST
PCYC was removed from the Best Ideas list, Wedbush said. Patient assistance programs for Imbruvica will be restricted.
Skittish buyers are only nibbling and leaving plenty of good cheap stocks for you.
Bullish
Oct 11, 2013 | 7:37 AM EDT
PCYC was upgraded from Neutral to Buy, Goldman Sachs said. $170 price target. ibruttinib could generate $7.5 billion of peak annual sal...
This trend is a good indication that business is going well.

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.